Matthieu Edelman

Matthieu Edelman is a seasoned marketing executive at Sanofi, where roles have included Head of COVID Franchise Marketing and Global Brand Lead for various products such as Beyfortus and Meninge. With a strong background in diabetes sales leadership, Matthieu has successfully led significant initiatives, including the launch of PRALUENT, a pioneering PCSK-9 inhibitor, and the commercial launch of lixisenatide. Previous experience encompasses strategic oversight as Senior Director in patient marketing and project leadership in the North America Pharmaceuticals division. Prior to Sanofi, Matthieu worked at Arthur Andersen as a consultant, auditing financial statements and advising pharmaceutical companies. Educational qualifications include a Master's degree from the University of Oxford and advanced studies in Health Economics and European Regulatory Affairs from Université Paris Cité.